Peptides are trending. That sentence alone should prompt caution in anyone who has watched a decade of wellness trends move from enthusiast forums to Instagram to mainstream medicine. But the trend, in this case, is tracking something real. The question — and it is the only question worth asking — is: which peptides, at which doses, from which sources, supervised by whom?
I prescribe peptides. I am also particular about which ones, why, and what the regulatory and evidence landscape actually looks like in 2026. This is that map.
What are peptides, and why are they having a moment?
Peptides are short chains of amino acids — the building blocks of proteins — that function as signaling molecules in the body. They bind to specific receptors and modulate processes: growth hormone release, cellular repair, collagen production, inflammation, sleep, metabolism. The body makes them naturally. The therapeutic interest lies in using exogenous (externally administered) peptides to amplify or restore these signals as they diminish with age, injury, or metabolic dysfunction.
The enthusiasm is warranted because the mechanism is elegant: you are working with the body’s own signaling architecture, not overriding it. The caution is warranted because elegant mechanisms and sloppy execution produce exactly the same outcome as no mechanism at all — and the unregulated peptide market is almost entirely sloppy execution.
The gray-market problem — and what we do differently
If you have spent any time searching for peptides online, you have encountered “research chemical” suppliers. These are companies selling peptides labeled “not for human use” — a legal loophole that shifts liability to the buyer. The peptides themselves may be legitimate compounds. The purity, sterility, dosing accuracy, and storage conditions almost certainly are not laboratory-grade.
What this means clinically: you do not know what you are injecting. The contamination risk is real. The dosing is uncontrolled. There is no physician of record, no baseline labs, no monitoring, and no one accountable when something goes wrong. This is not a protocol. It is an experiment with your own biology.
At The Charleston Atelier, every peptide I prescribe is sourced through licensed compounding pharmacies — facilities that operate under USP standards, conduct third-party purity testing, and require a valid prescription from a licensed physician. The difference is not philosophical. It is the difference between knowing what is in the vial and hoping.
Which peptides are legally prescribable in 2026?
The regulatory landscape shifted meaningfully in 2024 when the FDA reclassified several peptides — including BPC-157 and TB-500 — as “bulk drug substances under consideration,” which effectively removed them from the list of compounds that compounding pharmacies could legally prepare. That list continues to evolve. Here is where things stand as of 2026 for the compounds I most commonly use:
- Sermorelin — a GHRH analogue that stimulates the pituitary to release growth hormone naturally. Compoundable. Strong safety profile. Well-suited to patients experiencing the age-related decline in GH output that begins in the late 30s.
- CJC-1295 / Ipamorelin — a GHRH/GHRP combination that produces a more sustained GH pulse. Compoundable in combination. Used for body composition, recovery, and sleep quality.
- NAD+ (nicotinamide adenine dinucleotide) — a coenzyme central to mitochondrial energy production and DNA repair, levels of which decline significantly with age. Available as IV infusion and subcutaneous injection. The subcutaneous daily dosing protocol is what I have been most interested in: supporting individual cell health, preventing aging at the cellular level, with a practical daily ritual that compounds over time.
- PT-141 (Bremelanotide) — FDA-approved for hypoactive sexual desire disorder in premenopausal women; used off-label in men. Compoundable.
- Thymosin Alpha-1 — an immune-modulating peptide with a long track record in international medicine. Compoundable.
Peptide therapy versus buying online: the real difference
I am frequently asked whether the peptides purchased through gray-market research chemical suppliers are “the same thing” as what I prescribe. The compound may be identical on paper. Everything else differs.
Physician-prescribed peptide therapy includes: an intake assessment, baseline labs (at minimum: IGF-1, comprehensive metabolic, CBC, hormone panel as relevant), individualized dosing, a defined protocol duration, and follow-up monitoring. The goal is not to administer a compound. The goal is to shift a measurable biomarker in a direction that serves a clinical objective — whether that is improved sleep architecture, body composition change, immune resilience, or something else entirely.
Who is a good candidate for peptide therapy near Charleston?
The candidates I see most frequently are patients in their late 30s through mid-50s who feel the gap between how they function and how they want to function — recovery that takes longer, sleep that is lighter, body composition that resists their efforts, energy that is no longer reliable. These are not pathological complaints. They are the early signatures of the metabolic and hormonal shifts that accelerate in midlife, and they respond well to targeted peptide intervention when paired with the foundational elements: sleep, training, nutrition, and an honest metabolic baseline.
Peptide therapy is not a shortcut. It is a signal amplifier. It works best when there is something worth amplifying.
If you are curious whether a peptide protocol is appropriate for where you are right now, the intake form is where we start. I will tell you honestly what I think will and will not move the needle for you.
— Kendall Phelps-Polirer, MD · The Charleston Atelier · 83 Cannon Street, Charleston, SC